We are advancing a clinical-stage program to treat a range of multidrug-resistant pathogens. We are combining our deep expertise with Shionogi’s decades of successful infectious disease R&D in Japan to address the unmet medical needs of patients and healthcare professionals and to protect society from serious current and emerging Gram-negative bacterial infections.
Qpex Biopharma Product Pipeline
This compound and its use is investigational and it has not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview and should not be construed as a recommendation for use of any product for unapproved uses.Discovery
IND-Enabling
Phase 1
Phase 2
Phase 3
S-649228
Xeruborbactam + Cefiderocol
Focus Area:
Infections Due to Gram-Negative Bacteria
Delivery Method:
Intravenous Infusion
Status: Phase 1
Other Programs
Focus Area:
Resistant Bacterial Infections
Delivery Method:
Intravenous Infusion and
Oral
Oral
Status: Discovery